9 Month Cost-Effectiveness Analysis Possible If Companies Are Well-Prepared: Crecon Official

Crecon Medical Assessment COO Makoto Kobayashi A nine-month standard analysis period set under Japan’s new cost-effectiveness assessment (CEA) scheme has drawn fire from drug makers as being “way too short,” but an official of Crecon Medical Assessment, a company undertaking...read more